SUVENPHAR

Suven Pharmaceuticals Share Price

₹1,112.00 -1.1 (-0.1%)

27 Mar, 2025 15:41

SIP TrendupStart SIP in SUVENPHAR

Start SIP

Performance

  • Low
  • ₹1,080
  • High
  • ₹1,130
  • 52 Week Low
  • ₹598
  • 52 Week High
  • ₹1,360
  • Open Price₹1,119
  • Previous Close₹1,113
  • Volume287,736

Investment Returns

  • Over 1 Month -8.05%
  • Over 3 Month -3.19%
  • Over 6 Month -5.7%
  • Over 1 Year + 73.05%
SIP Lightning

Smart Investing Starts Here Start SIP with Suven Pharmaceuticals for Steady Growth!

Invest Now

Suven Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 101.4
  • PEG Ratio
  • -4.1
  • Market Cap Cr
  • 28,308
  • P/B Ratio
  • 14.3
  • Average True Range
  • 58.36
  • EPS
  • 10.97
  • Dividend Yield
  • 0
  • MACD Signal
  • 9.76
  • RSI
  • 43.38
  • MFI
  • 43.96

Suven Pharmaceuticals Financials

Suven Pharmaceuticals Technicals

EMA & SMA

Current Price
₹1,112.00
-1.1 (-0.1%)
pointer
  • stock-down_img
  • Bearish Moving Average 14
  • stock-up_img
  • Bullish Moving Average 2
  • 20 Day
  • ₹1,156.68
  • 50 Day
  • ₹1,147.89
  • 100 Day
  • ₹1,138.55
  • 200 Day
  • ₹1,066.62

Resistance and Support

1119.42 Pivot Speed
  • R3 1,252.98
  • R2 1,210.57
  • R1 1,161.83
  • S1 1,070.68
  • S2 1,028.27
  • S3 979.53

What's your outlook on Suven Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Suven Pharmaceuticals Ltd. is a leading pharmaceutical company specializing in contract development and manufacturing services (CDMO). It focuses on producing intermediates and active pharmaceutical ingredients (APIs), serving global pharmaceutical companies with innovative and high-quality solutions.

Suven Pharmaceuticals has an operating revenue of Rs. 1,048.49 Cr. on a trailing 12-month basis. An annual revenue de-growth of -20% needs improvement, Pre-tax margin of 39% is great, ROE of 14% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 5% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 16% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 62 which is a FAIR score but needs to improve its earnings, a RS Rating of 88 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 46 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Suven Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-28 Audited Results
2025-02-12 Quarterly Results
2024-11-12 Quarterly Results
2024-08-09 Quarterly Results
2024-05-30 Audited Results (Revised) per share(100%)Interim Dividend
Date Purpose Remarks
2022-09-12 INTERIM Rs.1.00 per share(100%)Interim Dividend
2022-09-12 SPECIAL Rs.5.00 per share(500%)Special Dividend
2022-05-17 INTERIM Re.1.00 per shaer (100%) Second Interim Dividend
2022-05-17 SPECIAL Rs.1.00 per share(100%)Special Dividend
2022-02-16 INTERIM Rs.1.00 per share(100%)Interim Dividend
View More

Suven Pharmaceuticals F&O

Suven Pharmaceuticals Shareholding Pattern

50.1%
13.15%
3.2%
10.84%
0%
9.81%
12.9%

About Suven Pharmaceuticals

  • NSE Symbol
  • SUVENPHAR
  • BSE Symbol
  • 543064
  • Managing Director
  • Dr. V Prasada Raju
  • ISIN
  • INE03QK01018

Similar Stocks to Suven Pharmaceuticals

Suven Pharmaceuticals FAQs

Suven Pharmaceuticals share price is ₹1,112 As on 27 March, 2025 | 15:27

The Market Cap of Suven Pharmaceuticals is ₹28307.6 Cr As on 27 March, 2025 | 15:27

The P/E ratio of Suven Pharmaceuticals is 101.4 As on 27 March, 2025 | 15:27

The PB ratio of Suven Pharmaceuticals is 14.3 As on 27 March, 2025 | 15:27

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23